Abstract:Abstract BACKGROUND Patients (pts) who do not achieve optimal response at standard dosing of biologic therapies or lose response over time often benefit from escalated doses of biologic therapies to manage moderate to severe Crohn’s disease (CD). Currently, no data exists on dose escalating risankizumab, an interleukin-23 inhibitor recently approved for the treatment of moderate to severe CD. This cohort study aimed to describe pt characteristics, insurance access, and response to therapy in pts prescribed risankizumab more frequently than the FDA-approved maintenance dosing of 180mg or 360mg every 8 weeks (wks). METHODS We conducted a retrospective single-center cohort study of pts with CD who were initiated on an escalated dose of risankizumab between June 2022 and July 2023. Pts must have received at least one escalated dose during the defined time frame for inclusion. Pt and disease characteristics, steps required to secure insurance access, and early treatment outcomes were collected from the electronic health record and reported descriptively. RESULTS A total of 211 pts completed three standard risankizumab intravenous induction infusions during the study period. Twelve pts were initiated on an escalated maintenance dosing frequency. All 12 pts received the 360mg dose. Seven pts were escalated to a frequency of every 6 wks (58%) and 5 pts were escalated to every 4 wks (42%). Pts were mostly female (67%) with a median age of 42 years (interquartile range [IQR] 30-52). The median number of previous biologic/small molecule drug failures was 4 (IQR 2-5). Eleven (92%) pts previously required a dose escalated biologic, the median years since diagnosis was 15 (IQR 10-17), and median body mass index was 25 kg/m2 (IQR 22-27). Six pts (50%) previously required surgical intervention. Pts received a median of 3 (IQR 2-3) risankizumab injections on standard dosing before a decision to escalate was made. Reasons for escalated dosing included colonoscopy/imaging/pathology results showing inflammation (n=7) or persistent symptoms (n=5). Five (42%) pts were able to access the escalated dose without an additional authorization, 5 (42%) required a prior authorization that was approved, and 2 (17%) required at least one level of appeal or peer to peer review. Through 10/03/2023, 6 pts had a documented improved response to the escalated dosing (50%), 3 remained stable (25%) and 3 had no change (25%) at a median of 88 days (IQR 72-103) from escalation. CONCLUSION This study demonstrated the need for heavily treatment-experienced pts with severe CD to dose escalate risankizumab, often requiring an additional insurance authorization. Most pts improved or remained stable on the escalated dosing, showing promise for risankizumab dose escalation outcomes. More research is needed to assess risankizumab dose escalation long-term outcomes and the role of trough levels.

P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study

Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

OP25 Patients with Moderate to Severe Crohn’s Disease with and Without Prior Biologic Failure Demonstrate Improved Endoscopic Outcomes with Risankizumab: Results from Phase 3 Induction and Maintenance Trials

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study

P848 Risankizumab Effectiveness in Ustekinumab-naïve and Ustekinumab-experienced Patients with Crohn’s Disease- Real-world Data from a Large Tertiary Center

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies

Efficacy and Safety of Risankizumab for Crohn's Disease in Patients from Asian Countries: a Post Hoc Subanalysis of the Global Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.

DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease

P775 Efficacy and safety of risankizumab in children with Crohn’s disease: A preliminary report

RISANKIZUMAB DOSE ESCALATION IN PATIENTS WITH CROHN'S DISEASE

S1472 Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study

Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areas

OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study

S1156 A Multi-Center Study of the Outcomes of Risankizumab Use Stratified by Prior Ustekinumab Exposure in Patients With Crohn's Disease: A Real-World Experience

OP36 Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials